A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Novavax Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,064,783 shares of NVAX stock, worth $17.5 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,064,783
Previous 1,110,183 85.99%
Holding current value
$17.5 Million
Previous $14.1 Million 85.56%
% of portfolio
0.04%
Previous 0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.71 - $17.11 $10.2 Million - $16.3 Million
954,600 Added 85.99%
2,064,783 $26.1 Million
Q2 2024

Aug 09, 2024

BUY
$3.89 - $20.97 $4.32 Million - $23.3 Million
1,110,183 New
1,110,183 $14.1 Million
Q2 2023

Aug 11, 2023

SELL
$6.67 - $9.52 $20.7 Million - $29.5 Million
-3,101,500 Reduced 87.6%
438,883 $3.26 Million
Q1 2023

May 12, 2023

BUY
$5.76 - $12.48 $4.14 Million - $8.97 Million
718,700 Added 25.47%
3,540,383 $24.5 Million
Q4 2022

Feb 13, 2023

BUY
$8.86 - $25.04 $17.2 Million - $48.6 Million
1,941,100 Added 220.43%
2,821,683 $29 Million
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $16 Million - $67 Million
880,583 New
880,583 $16 Million
Q2 2021

Aug 13, 2021

SELL
$121.0 - $257.67 $81.4 Million - $173 Million
-672,683 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$112.98 - $319.93 $76 Million - $215 Million
672,683 New
672,683 $122 Million
Q4 2020

Feb 10, 2021

SELL
$78.74 - $139.5 $16.4 Million - $29.1 Million
-208,583 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$79.44 - $178.51 $16.6 Million - $37.2 Million
208,583 New
208,583 $22.6 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $662M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.